Xiaoduo Fan

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9240261/publications.pdf

Version: 2024-02-01

115 papers	3,658 citations	94433 37 h-index	161849 54 g-index
116 all docs	116 docs citations	116 times ranked	5068 citing authors

#	Article	IF	Citations
1	Improvement of adjunctive berberine treatment on negative symptoms in patients with schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2022, 272, 633-642.	3.2	6
2	The effect of serum lipids and short-chain fatty acids on cognitive functioning in drug-naÃ¯ve, first episode schizophrenia patients. Psychiatry Research, 2022, 313, 114582.	3.3	12
3	A Pilot Remote Drama Therapy Program Using the Co-active Therapeutic Theater Model in People with Serious Mental Illness. Community Mental Health Journal, 2022, 58, 1613-1620.	2.0	2
4	Sequential Multiple-Assignment Randomized Trials to Compare Antipsychotic Treatments (SMART-CAT) in first-episode schizophrenia patients: Rationale and trial design. Schizophrenia Research, 2021, 230, 87-94.	2.0	2
5	A narrative review of mindfulness-based therapy for schizophrenia, co-occurring substance use and comorbid cardiometabolic problems. Psychiatry Research, 2021, 296, 113707.	3.3	4
6	Association of Aripiprazole With Reduced Hippocampal Atrophy During Maintenance Treatment of First-Episode Schizophrenia. Journal of Clinical Psychopharmacology, 2021, 41, 244-249.	1.4	3
7	Effect of citalopram on hippocampal volume in first-episode schizophrenia: Structural MRI results from the DECIFER trial. Psychiatry Research - Neuroimaging, 2021, 312, 111286.	1.8	3
8	The Role of Butyric Acid in Treatment Response in Drug-NaÃ¯ve First Episode Schizophrenia. Frontiers in Psychiatry, 2021, 12, 724664.	2.6	14
9	Gut microbial biomarkers for the treatment response in first-episode, drug-naÃ¯ve schizophrenia: a 24-week follow-up study. Translational Psychiatry, 2021, 11, 422.	4.8	25
10	Reduced connectivity in anterior cingulate cortex as an early predictor for treatment response in drug-naive, first-episode schizophrenia: A global-brain functional connectivity analysis. Schizophrenia Research, 2020, 215, 337-343.	2.0	24
11	Treatment and services for psychosis: Are college campuses a novel frontier for early detection and intervention?. Psychiatry Research, 2020, 284, 112699.	3.3	2
12	Solute Carrier Family 1 (SLC1A1) Contributes to Susceptibility and Psychopathology Symptoms of Schizophrenia in the Han Chinese Population. Frontiers in Psychiatry, 2020, 11, 559210.	2.6	3
13	Insulin Resistance and Oxidative Stress: In Relation to Cognitive Function and Psychopathology in Drug-NaÃ¯ve, First-Episode Drug-Free Schizophrenia. Frontiers in Psychiatry, 2020, 11, 537280.	2.6	13
14	Dual diagnosis theater: A pilot drama therapy program for individuals with serious mental illness and substance use disorder. Schizophrenia Research, 2020, 230, 95-97.	2.0	3
15	The impact of COVID-19 on individuals living with serious mental illness. Schizophrenia Research, 2020, 222, 3-5.	2.0	61
16	Current understanding on the role of nitric oxide and therapeutic potential of NO supplementation in schizophrenia. Schizophrenia Research, 2020, 222, 23-30.	2.0	11
17	Association of DTNBP1 With Schizophrenia: Findings From Two Independent Samples of Han Chinese Population. Frontiers in Psychiatry, 2020, 11, 446.	2.6	7
18	Air pollution and hippocampal atrophy in first episode schizophrenia. Schizophrenia Research, 2020, 218, 63-69.	2.0	7

#	Article	IF	Citations
19	The role of altered brain structural connectivity in resilience, vulnerability, and disease expression to schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2020, 101, 109917.	4.8	6
20	Effect of Citalopram on Hippocampal Atrophy in First-Episode Psychosis: Structural MRI Results From the DECIFER Trial. Biological Psychiatry, 2020, 87, S166.	1.3	0
21	Enhanced baseline activity in the left ventromedial putamen predicts individual treatment response in drug-naive, first-episode schizophrenia: Results from two independent study samples. EBioMedicine, 2019, 46, 248-255.	6.1	24
22	Reduced Brain Activity in the Right Putamen as an Early Predictor for Treatment Response in Drug-Naive, First-Episode Schizophrenia. Frontiers in Psychiatry, 2019, 10, 741.	2.6	20
23	Methamphetamineâ€associated psychosis: Clinical presentation, biological basis, and treatment options. Human Psychopharmacology, 2019, 34, e2710.	1.5	38
24	Pilot lifestyle education intervention for patients with severe mental illness during the inpatient stay. Asian Journal of Psychiatry, 2019, 40, 15-17.	2.0	4
25	Insomnia in patients with schizophrenia: current understanding and treatment options. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 92, 235-242.	4.8	36
26	Citalopram in first episode schizophrenia: The DECIFER trial. Schizophrenia Research, 2019, 208, 331-337.	2.0	15
27	Dysfunction in Serotonergic and Noradrenergic Systems and Somatic Symptoms in Psychiatric Disorders. Frontiers in Psychiatry, 2019, 10, 286.	2.6	43
28	Mixed methods to explore factors associated with the decline of patients in the methadone maintenance treatment program in Shanghai, China. Harm Reduction Journal, 2019, 16, 34.	3.2	5
29	Repetitive transcranial magnetic stimulation as an adjunctive treatment for negative symptoms and cognitive impairment in patients with schizophrenia: a randomized, double-blind, sham-controlled trial . Neuropsychiatric Disease and Treatment, 2019, Volume 15, 1141-1150.	2.2	27
30	The Possible Role of the Angiotensin System in the Pathophysiology of Schizophrenia: Implications for Pharmacotherapy. CNS Drugs, 2019, 33, 539-547.	5.9	20
31	Creative art therapy for mental illness. Psychiatry Research, 2019, 275, 129-136.	3.3	63
32	Efficacy and Tolerability of Adjunctive Intravenous Sodium Nitroprusside Treatment for Outpatients With Schizophrenia. JAMA Psychiatry, 2019, 76, 691.	11.0	18
33	Adjunctive telmisartan treatment on body metabolism in clozapine or olanzapine treated patients with schizophrenia: a randomized, double blind, placebo controlled trial. Psychopharmacology, 2019, 236, 1949-1957.	3.1	3
34	The Miniature Robotic Needling Device in Brachytherapy: Design and Modeling - An Approach Towards Smart Needle System. , 2019, , .		2
35	Association of Hippocampal Atrophy With Duration of Untreated Psychosis and Molecular Biomarkers During Initial Antipsychotic Treatment of First-Episode Psychosis. JAMA Psychiatry, 2018, 75, 370.	11.0	56
36	No Effect of Adjunctive Minocycline Treatment on Body Metabolism in Patients With Schizophrenia. Journal of Clinical Psychopharmacology, 2018, 38, 125-128.	1.4	4

#	Article	IF	Citations
37	Racial disparity in mental disorder diagnosis and treatment between non-hispanic White and Asian American patients in a general hospital. Asian Journal of Psychiatry, 2018, 34, 78-83.	2.0	8
38	Changes in plasma levels of nitric oxide metabolites and negative symptoms after 16-week minocycline treatment in patients with schizophrenia. Schizophrenia Research, 2018, 199, 390-394.	2.0	10
39	Abnormal regional homogeneity as a potential imaging biomarker for adolescent-onset schizophrenia: A resting-state fMRI study and support vector machine analysis. Schizophrenia Research, 2018, 192, 179-184.	2.0	80
40	Gray matter volume showed dynamic alterations in methamphetamine users at 6 and 12 months abstinence: A longitudinal voxel-based morphometry study. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2018, 81, 350-355.	4.8	19
41	Salsalate as an adjunctive treatment for psychopathology and cognition in patients with schizophrenia. International Clinical Psychopharmacology, 2018, 33, 88-91.	1.7	4
42	Microglia activation in the offspring of prenatal Poly I: C exposed rats: a PET imaging and immunohistochemistry study. Annals of General Psychiatry, 2018, 31, e000006.	3.1	17
43	Disrupted asymmetry of inter- and intra-hemispheric functional connectivity in patients with drug-naive, first-episode schizophrenia and their unaffected siblings. EBioMedicine, 2018, 36, 429-435.	6.1	32
44	Changes in metabolism and microbiota after 24-week risperidone treatment in drug naÃ¯ve, normal weight patients with first episode schizophrenia. Schizophrenia Research, 2018, 201, 299-306.	2.0	112
45	Naltrexone and Bupropion Combination Treatment for Smoking Cessation and Weight Loss in Patients With Schizophrenia. Frontiers in Pharmacology, 2018, 9, 181.	3.5	18
46	Impaired cue identification and intention retrieval underlie prospective memory deficits in patients with first-episode schizophrenia. Australian and New Zealand Journal of Psychiatry, 2017, 51, 270-277.	2.3	12
47	Antioxidant and anti-inflammatory nutrient status, supplementation, and mechanisms in patients with schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2017, 78, 1-11.	4.8	61
48	The effect of adjunctive telmisartan treatment on psychopathology and cognition in patients with schizophrenia. Acta Psychiatrica Scandinavica, 2017, 136, 465-472.	4.5	18
49	Altered resting-state intra- and inter- network functional connectivity in patients with persistent somatoform pain disorder. PLoS ONE, 2017, 12, e0176494.	2.5	38
50	Decreased Functional Connectivity of Insular Cortex in Drug NaÃ¯ve First Episode Schizophrenia: In Relation to Symptom Severity. PLoS ONE, 2017, 12, e0167242.	2.5	16
51	Resting-state functional connectivity changes within the default mode network and the salience network after antipsychotic treatment in early-phase schizophrenia. Neuropsychiatric Disease and Treatment, 2017, Volume 13, 397-406.	2.2	52
52	Relationship between serum uric acid level and cardiometabolic risks in nondiabetic patients with schizophrenia. International Clinical Psychopharmacology, 2016, 31, 51-56.	1.7	3
53	Altered Neural Correlates of Emotion Associated Pain Processing in Persistent Somatoform Pain Disorder: An fMRI Study. Pain Practice, 2016, 16, 969-979.	1.9	14
54	Vitamin D in schizophrenia: a clinical review. Evidence-Based Mental Health, 2016, 19, 6-9.	4.5	62

#	Article	IF	Citations
55	Abnormal white matter microstructure in drug-naive first episode schizophrenia patients before and after eight weeks of antipsychotic treatment. Schizophrenia Research, 2016, 172, 1-8.	2.0	75
56	The Clinical Value, Principle, and Basic Practical Technique of Mindfulness Intervention. Shanghai Archives of Psychiatry, 2016, 28, 121-130.	0.7	6
57	Hippocampal volume reduction in female but not male recent abstinent methamphetamine users. Behavioural Brain Research, 2015, 289, 78-83.	2.2	22
58	Dysfunctional resting-state connectivities of brain regions with structural deficits in drug-naive first-episode schizophrenia adolescents. Schizophrenia Research, 2015, 168, 353-359.	2.0	31
59	Decreased cortical thickness in drug naÃ¯ve first episode schizophrenia: In relation to serum levels of BDNF. Journal of Psychiatric Research, 2015, 60, 22-28.	3.1	34
60	Schizophrenia and the gutâ€“brain axis. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2015, 56, 155-160.	4.8	110
61	Neural Correlates of the Preserved Inhibition of Return in Schizophrenia. PLoS ONE, 2015, 10, e0119521.	2.5	1
62	APOA-I: A Possible Novel Biomarker for Metabolic Side Effects in First Episode Schizophrenia. PLoS ONE, 2014, 9, e93902.	2.5	14
63	Fat-mass and obesity-associated gene polymorphisms and weight gain after risperidone treatment in first episode schizophrenia. Behavioral and Brain Functions, 2014, 10, 35.	3.3	25
64	What Can the Medical Education Do for Eliminating Stigma and Discrimination Associated with Mental Illness among Future Doctors? Effect of Clerkship Training on Chinese Students' Attitudes. International Journal of Psychiatry in Medicine, 2014, 47, 241-254.	1.8	32
65	Prolactin serum levels correlate with inflammatory status in drug-naÃ¯ve first-episode schizophrenia. World Journal of Biological Psychiatry, 2014, 15, 546-552.	2.6	20
66	Changes in pro-inflammatory cytokines and body weight during 6-month risperidone treatment in drug naÃ¯ve, first-episode schizophrenia. Psychopharmacology, 2014, 231, 319-325.	3.1	87
67	A randomized placebo-controlled pilot study of pravastatin as an adjunctive therapy in schizophrenia patients: Effect on inflammation, psychopathology, cognition and lipid metabolism. Schizophrenia Research, 2014, 159, 395-403.	2.0	51
68	Phenotypic characteristics in metabolically healthy but obese patients with schizophrenia. Psychiatry Research, 2014, 220, 71-75.	3.3	0
69	Serum levels of BDNF, folate and homocysteine: In relation to hippocampal volume and psychopathology in drug naÃ¯ve, first episode schizophrenia. Schizophrenia Research, 2014, 159, 51-55.	2.0	40
70	Decreased gray matter volume in the left middle temporal gyrus as a candidate biomarker for schizophrenia: A study of drug naive, first-episode schizophrenia patients and unaffected siblings. Schizophrenia Research, 2014, 159, 43-50.	2.0	43
71	Hippocampal and orbital inferior frontal gray matter volume abnormalities and cognitive deficit in treatment-naive, first-episode patients with schizophrenia. Schizophrenia Research, 2014, 152, 339-343.	2.0	68
72	Activation of Th17 cells in drug naÃ¯ve, first episode schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2014, 51, 78-82.	4.8	102

#	Article	IF	Citations
73	Effects of 420â€nm intense pulsed light in an acne animal model. Journal of the European Academy of Dermatology and Venereology, 2013, 27, 1168-1171.	2.4	19
74	Prospective memory performance in patients with drug-naÃ¯ve, first-episode psychosis. Schizophrenia Research, 2013, 143, 285-290.	2.0	22
75	Elevated levels of adiponectin and other cytokines in drug naÃ¯ve, first episode schizophrenia patients with normal weight. Schizophrenia Research, 2013, 150, 269-273.	2.0	76
76	Comparison of metabolic effects of ziprasidone versus olanzapine treatment in patients with first-episode schizophrenia. Psychopharmacology, 2013, 225, 627-635.	3.1	31
77	Metabolic effects of adjunctive aripiprazole in clozapineâ€treated patients with schizophrenia. Acta Psychiatrica Scandinavica, 2013, 127, 217-226.	4.5	46
78	No effect of adjunctive, repeated dose intranasal insulin treatment on body metabolism in patients with schizophrenia. Schizophrenia Research, 2013, 146, 40-45.	2.0	14
79	Review: non-steroidal anti-inflammatory drugs may reduce schizophrenia symptom severity in the short term when added to antipsychotics. Evidence-Based Mental Health, 2013, 16, 10-10.	4.5	4
80	Human Papillomavirus E7 Induces Rereplication in Response to DNA Damage. Journal of Virology, 2013, 87, 1200-1210.	3.4	30
81	No Effect of Adjunctive, Repeated-Dose Intranasal Insulin Treatment on Psychopathology and Cognition in Patients With Schizophrenia. Journal of Clinical Psychopharmacology, 2013, 33, 226-230.	1.4	14
82	Species-specific factors mediate extensive heterogeneity of mRNA 3â€² ends in yeasts. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 11073-11078.	7.1	47
83	Duration of Untreated Psychosis Is Associated with Temporal and Occipitotemporal Gray Matter Volume Decrease in Treatment NaÃ¯ve Schizophrenia. PLoS ONE, 2013, 8, e83679.	2.5	44
84	Rosiglitazone and cognitive function in clozapine-treated patients with schizophrenia: A pilot study. Psychiatry Research, 2012, 200, 79-82.	3.3	15
85	Both physical activity and food intake are associated with metabolic risks in patients with schizophrenia. Schizophrenia Research, 2012, 140, 260-261.	2.0	12
86	Effects of modafinil on weight, glucose and lipid metabolism in clozapine-treated patients with schizophrenia. Schizophrenia Research, 2011, 130, 53-56.	2.0	18
87	Placebo-Controlled Pilot Study of Ramelteon for Adiposity and Lipids in Patients With Schizophrenia. Journal of Clinical Psychopharmacology, 2011, 31, 653-658.	1.4	31
88	No Effect of Single-Dose Intranasal Insulin Treatment on Verbal Memory and Sustained Attention in Patients With Schizophrenia. Journal of Clinical Psychopharmacology, 2011, 31, 231-234.	1.4	19
89	Triglyceride/High-Density Lipoprotein Cholesterol Ratio. Journal of Clinical Psychiatry, 2011, 72, 806-812.	2.2	40
90	Nucleosome depletion at yeast terminators is not intrinsic and can occur by a transcriptional mechanism linked to 3â€™-end formation. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 17945-17950.	7.1	79

#	Article	IF	Citations
91	Higher white blood cell counts are associated with an increased risk for metabolic syndrome and more severe psychopathology in non-diabetic patients with schizophrenia. Schizophrenia Research, 2010, 118, 211-217.	2.0	72
92	Phenotypic characteristics in metabolically obese but normal weight non-diabetic patients with schizophrenia. Schizophrenia Research, 2010, 124, 49-53.	2.0	7
93	Deficient inhibition of return in chronic but not first-episode patients with schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2010, 34, 961-967.	4.8	7
94	Analysis of peripheral immune activation in schizophrenia using quantitative reverse-transcription polymerase chain reaction (RT-PCR). Psychiatry Research, 2010, 176, 99-102.	3.3	42
95	Dietary saturated fat intake and glucose metabolism impairments in nondiabetic, nonobese patients with schizophrenia on clozapine or risperidone. Annals of Clinical Psychiatry, 2010, 22, 33-42.	0.6	16
96	Ziprasidone as an adjuvant for clozapineâ€•or olanzapineâ€•associated medical morbidity in chronic schizophrenia. Human Psychopharmacology, 2009, 24, 225-232.	1.5	19
97	A doubleâ€•blind, placeboâ€•controlled trial of rosiglitazone for clozapineâ€•induced glucose metabolism impairment in patients with Schizophrenia. Acta Psychiatrica Scandinavica, 2009, 119, 457-465.	4.5	38
98	Aripiprazole Added to Overweight and Obese Olanzapine-Treated Schizophrenia Patients. Journal of Clinical Psychopharmacology, 2009, 29, 165-169.	1.4	79
99	Waist Circumference is the Best Anthropometric Predictor for Insulin Resistance in Nondiabetic Patients with Schizophrenia Treated with Clozapine but not Olanzapine. Journal of Psychiatric Practice, 2009, 15, 251-261.	0.7	19
100	Modafinil for Clozapine-Treated Schizophrenia Patients. Journal of Clinical Psychiatry, 2009, 70, 1674-1680.	2.2	70
101	Posttraumatic stress disorder, cognitive function and quality of life in patients with schizophrenia. Psychiatry Research, 2008, 159, 140-146.	3.3	49
102	Race Moderates Age-Related Cognitive Decline in Type 2 Diabetes. Experimental Aging Research, 2008, 34, 114-125.	1.2	8
103	Light to Moderate Alcohol Drinking is Associated with Higher Cognitive Function in Males with Type 2 Diabetes. Experimental Aging Research, 2008, 34, 126-137.	1.2	5
104	Waist circumference does not predict insulin resistance in African American schizophrenia patients. International Journal of Culture and Mental Health, 2008, 1, 93-104.	0.6	1
105	Elevated serum levels of C-reactive protein are associated with more severe psychopathology in a subgroup of patients with schizophrenia. Psychiatry Research, 2007, 149, 267-271.	3.3	138
106	Sexual functioning, psychopathology and quality of life in patients with schizophrenia. Schizophrenia Research, 2007, 94, 119-127.	2.0	60
107	Inflammation and schizophrenia. Expert Review of Neurotherapeutics, 2007, 7, 789-796.	2.8	106
108	A double-blind, placebo-controlled trial of sibutramine for clozapine-associated weight gain. Acta Psychiatrica Scandinavica, 2007, 115, 101-105.	4.5	50

#	Article	IF	Citations
109	Elevated Hemoglobin A1c as a Possible Indicator of Diabetes Mellitus and Diabetic Ketoacidosis in Schizophrenia Patients Receiving Atypical Antipsychotics. Journal of Clinical Psychiatry, 2007, 68, 533-541.	2.2	79
110	Higher Fasting Serum Insulin Is Associated with Increased Resting Energy Expenditure in Nondiabetic Schizophrenia Patients. Biological Psychiatry, 2006, 60, 1372-1377.	1.3	10
111	Higher fasting serum insulin levels are associated with a better psychopathology profile in acutely ill non-diabetic inpatients with schizophrenia. Schizophrenia Research, 2006, 86, 30-35.	2.0	21
112	Ultrasound surgery using multiple sonicationsâ€"Treatment time considerations. Ultrasound in Medicine and Biology, 1996, 22, 471-482.	1.5	151
113	A study of various parameters of spherically curved phased arrays for noninvasive ultrasound surgery. Physics in Medicine and Biology, 1996, 41, 591-608.	3.0	60
114	Control of the necrosed tissue volume during noninvasive ultrasound surgery using a 16-element phased array. Medical Physics, 1995, 22, 297-306.	3.0	67
115	Walking together: Exploring perspectives, attitudes, and barriers on nutrition and exercise among individuals with serious mental illness. Current Psychology, 0, , 1.	2.8	0